ArticlePoultry science2026
Oral immunization with recombinant Lactococcus lactis expressing VP3 and VP3-IFNα fusion protein protects ducklings against novel goose parvovirus infection.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel goose parvovirus (NGPV), an emerging variant of goose parvovirus, is the causative agent of short beak and dwarfism syndrome (SBDS) in ducks, posing a substantial threat to the global waterfowl industry. There is an urgent need for safe and convenient vaccines that can effectively induce mucosal immunity. This study aimed to develop and evaluate the immunogenicity and protective efficacy of an oral vaccine based on recombinant Lactococcus lactis (L. lactis) expressing the major capsid protein VP3 of NGPV, with or without fusion to duck interferon-alpha (IFNα). Codon-optimized genes encoding NGPV VP3 and a VP3-IFNα fusion were cloned into the nisin-inducible pNZ8149 vector and expressed in L. lactis NZ3900. One-day-old ducklings were orally immunized three times with PBS, empty-vector L. lactis (L.l-Empty), recombinant L. lactis expressing VP3 (L.l-VP3), or the VP3-IFNα fusion (L.l-VP3-IFNα). Humoral (serum IgG), mucosal (intestinal sIgA), and cellular (serum IFN-γ, IL-10) immune responses were assessed. Lymphocyte proliferation was evaluated using a CCK-8 assay. Immunized ducklings were subsequently challenged with a virulent NGPV strain (NMG21), and protection was evaluated based on viral shedding (qPCR), mortality, and intestinal histopathology. The results demonstrated that both recombinant strains successfully expressed the target proteins. Oral immunization with L.l-VP3 and L.l-VP3-IFNα significantly induced VP3-specific serum IgG, intestinal sIgA, and elevated levels of IFN-γ and IL-10. Notably, the L.l-VP3-IFNα group elicited stronger sIgA and cytokine responses. Following the challenge, both vaccinated groups exhibited significantly reduced viral shedding and were protected from severe intestinal damage, with the L.l-VP3-IFNα group showing the lowest viral load. Therefore, recombinant L. lactis expressing NGPV VP3, particularly when fused with IFNα, serves as an effective oral vaccine candidate, inducing comprehensive systemic and mucosal immunity and providing significant protection against NGPV challenge. This study established a foundation for developing live bacterial vaccines against waterfowl parvoviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.